News

Medical Device Market Access: What are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Programme?

Introduction

In England, market access for innovative medical devices is a less structured pathway than it is for pharmaceuticals. In most instances, it is the manufacturer’s prerogative to decide which access route is most suitable for their device and diagnostic. If they choose to, manufacturers can follow a local or regional Clinical Commissioning Group (CCG) driven approach, where their product is adopted incrementally on an individual CCG-by-CCG basis. While not a mandatory requirement, it is possible for the manufacturer to put forward their device for NICE assessment. Alternatively, physicians or CCGs can request a NICE evaluation, or it can be identified proactively by NICE themselves. This article will look at why manufacturers may choose to submit their product rather than solely pursuing a local, CCG-driven approach.

NICE appraisal approach

The National Institute for Health and Care Excellence (NICE) has several different programs, depending on the type of technology to be assessed (i.e. […]

By |2019-11-13T11:04:43+00:00November 13th, 2019|News|Comments Off on Medical Device Market Access: What are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Programme?

Fatima Chunara & Mike Thomas at Leeds University

Fatima and Mike are presenting ‘How to get into Consulting‘ this afternoon at Leeds University.

Leeds Uni Consulting Event

Interested in attending? Register by typing the links in the above advert into the relevant social media app.

By |2019-11-08T14:01:28+00:00November 12th, 2019|Careers, News|Comments Off on Fatima Chunara & Mike Thomas at Leeds University

Remap had a great time at ISPOR this year in Copenhagen

The team were very productive at ISPOR this year, where Fatima Chunara gave a fantastic podium presentation to an audience of over 300 people on the topic: “Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019”. The details of the presentation can be found here.

We also successfully presented 4 posters on various subjects:

By |2019-11-08T13:25:06+00:00November 8th, 2019|News|Comments Off on Remap had a great time at ISPOR this year in Copenhagen

Looking forward to ISPOR Copenhagen next week

The Remap Team are excited to be exhibiting at ISPOR Copenhagen next week, where we will be revealing something special so be sure to come along to Booth C3-047 to see what it is!

4-6 November 2019.

Contact us to arrange a meeting.

By |2019-11-01T13:29:02+00:00November 1st, 2019|News|Comments Off on Looking forward to ISPOR Copenhagen next week

Final preparations for ISPOR Copenhagen

The Remap Team are making final preparations this week ready for ISPOR Copenhagen.

We will be in Booth C3-047 so be sure to come and meet us to see how we can help you with your Market Access or Pricing & Reimbursement requirements.

4-6 November 2019.

Contact us to arrange a meeting.

By |2019-10-24T12:24:13+00:00October 24th, 2019|News|Comments Off on Final preparations for ISPOR Copenhagen

Our 5th abstract accepted at ISPOR 2019

“Are acute therapies and curative drugs more affordable than chronic treatments in rare diseases? An analysis of the top 20 most expensive drugs in the US”

OBJECTIVES

Innovative drugs for rare diseases are increasingly expensive. Previous publications assess annual cost and group together gene/acute therapies and chronic treatments, which may not provide a complete picture. This study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, on an annual and lifetime basis to provide an accurate comparison.

METHODS

A literature review of PubMed and grey databases including terms: high cost, most expensive treatment, therapy, annual, lifetime was conducted to identify the most expensive drugs in the US on an annual and lifetime cost basis. 25 products were identified, and drug costs calculated using dosing, USD WAC prices, age of disease onset and life-expectancy to arrive at the top 20 most costly treatments from an annual and lifetime perspective.

RESULTS

On an annual basis, the […]

By |2019-10-25T11:06:57+00:00October 17th, 2019|News|Comments Off on Our 5th abstract accepted at ISPOR 2019

Are EUnetHTAs’ joint assessments facilitating HTA cooperation or just another barrier to market access?

The European Network for HTA (EUnetHTA) was set up in 2006, to promote more collaboration and harmonisation in the EU, by linking national Health Technology Assessment (HTA) agencies, research institutions and health ministries. EUnetHTA was built to find the answer to a single question: How to create, facilitate, and promote sustainable Health Technology Assessment (HTA) cooperation in Europe?

To help address this question, EUnetHTA has developed and is piloting a joint relative effectiveness HTA, known as joint assessments, produced by at least four EUnetHTA partners in different European countries. The aim of these joint assessments is the production and use of reliable, timely, transparent reports to support patients’ access to effective health technologies.

These joint assessments currently focus on the clinical considerations of an HTA using the processes, guidelines and the HTA Core Model®, developed by EUnetHTA over the past nine years. To date, five joint assessments have been […]

By |2019-10-16T16:57:22+00:00October 11th, 2019|News|Comments Off on Are EUnetHTAs’ joint assessments facilitating HTA cooperation or just another barrier to market access?

Graham Foxon interviewed in CAR T-Therapy news articles

Graham was interviewed recently by Leela Barham, a freelance journalist for Pink Sheet News on two articles:

Click the links above to access the articles and read Graham’s opinions on the topic.

By |2019-10-10T17:56:05+00:00October 11th, 2019|News|Comments Off on Graham Foxon interviewed in CAR T-Therapy news articles